BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance

December 5, 2016
Mike Ward, global director of content for Informa Pharma Intelligence, chats with Deciphera Pharmaceuticals' CEO Michael Taylor about the company's cell-signaling technology, based on a clinical pipeline of kinase inhibitors. Taylor also explains the company's strategy of addressing drug resistance in cancer. By simultaneously blocking multiple cancer signaling mechanisms, Deciphera believes its therapies can control drug-resistant mutations while improving therapeutic potency, durability, and selectivity. Its pipeline includes three Phase I assets and a preclinical program.
Previous Video
BIO-Europe® 2016: Promethera extends series C on interest from Asian investors
BIO-Europe® 2016: Promethera extends series C on interest from Asian investors

Dr. John Tchelingerian, CEO of Promethera Biosciences, talks to Scrip senior writer Lucie Ellis on the side...

Next Video
BIO-Europe® 2016: Inositec CEO on 2017 financing plans
BIO-Europe® 2016: Inositec CEO on 2017 financing plans

Mattias Ivarsson, co-founder and CEO of Inositec, talks to Lucie Ellis, senior writer at Scrip, about the c...